

September 26, 2019

Meiji Seika Pharma reinforces Medreich's pharmaceutical
CMO/CDMO services and product supply for Japanese market

Meiji Seika Pharma Co., Ltd. (Head office: Chuo-ku, Tokyo, President: Daikichiro Kobayashi, "Meiji") today announced that it reinforces pharmaceutical CMO/CDMO services and product supply at its Indian subsidiary Medreich Limited (Head office: Bengaluru, Karnataka, India, Managing Director: Pankaj Garg, "Medreich") for Japanese market. For this purpose, Meiji newly establishes "Japan Business Development Group" subordinated to Medreich Operation Department at the Headquarters on October 1st, 2019. The group dedicated to provide information on capability of Medreich's CMO/CDMO services, and support product supply to Japanese Market.

The annual sales in the market for generic drugs in Japan has exceeded 1 trillion yen per year and is expected to expand in the future. On the other hand, the drug prices have fallen significantly due to frequent NHI (National Health Insurance) drug price revisions, consequently manufacturers are exposed to severe price competition.

In order to meet this trend, Meiji has established a production and supply system that can stably supply products manufactured at Medreich. Meiji already supplies such products to the Japanese market through its subsidiary Me Pharma Co. Ltd. that has received high acclaim from the medical professionals as a cost-competitive, high-quality product. Meiji further improves this system and will provide products to pharmaceutical manufacturers other than Me Pharma.

Medreich has a state-of-the-art formulation line for Japan with a production capacity of 3 billion tablets per year, and can manufacture products that meet the quality standards of the Japanese market, by applying the same manufacturing management standards as Meiji's factory in Japan.

Meiji will stably supply high-quality generic drugs at a low cost, open the future of generic drugs, and contribute to the health of people.